2025 | 2024 | ||||||
| Underlying | Non- | Underlying | Non- | ||||
| business | trading | business | trading | ||||
| performance | items | Total | performance | items | Total | ||
| Note | US$m | US$m | US$m | US$m | US$m | US$m | |
re-presented* | re-presented* | ||||||
| Revenue | 3 | ||||||
| Net operating costs | 4 | ( | ( | ( | ( | ( | ( |
| Change in fair value of investment properties | 11 | ( | ( | ||||
Operating profit/(loss) | ( | ( | |||||
| Net financing charges | 5 | ||||||
– financing charges | ( | ( | ( | ( | ( | ( | |
– financing income | |||||||
( | ( | ( | ( | ||||
| Share of results of associates and joint ventures | 6 | ||||||
– before change in fair value of investment properties | |||||||
– change in fair value of investment properties | |||||||
Profit/(loss) before tax | ( | ( | |||||
| Tax | 7 | ( | ( | ( | ( | ( | ( |
Profit/(loss) after tax | ( | ( | |||||
| Attributable to: | |||||||
Shareholders of the Company | ( | ( | |||||
Non-controlling interests | ( | ||||||
( | ( | ||||||
US ¢ | US ¢ | US ¢ | US ¢ | ||||
| Earnings/(loss) per share | 8 | ||||||
– basic | ( | ||||||
– diluted | ( |
| for the year ended 31 December 2025 | |||
2025 | 2024 | ||
| Note | US$m | US$m | |
Profit/(loss) for the year | ( | ||
| Other comprehensive income/(expense) | |||
| Items that will not be reclassified to profit or loss: | |||
Remeasurements of defined benefit plans | |||
| Tax on items that will not be reclassified | 7 | ( | |
| Items that may be reclassified subsequently to profit or loss: | |||
| Net exchange translation differences | |||
– net gain arising during the year | |||
– transfer to profit and loss | ( | ||
| Cash flow hedges | |||
– net (loss)/gain arising during the year | ( | ||
– transfer to profit and loss | ( | ||
( | |||
| Tax relating to items that may be reclassified | 7 | ( | |
| Share of other comprehensive income/(expense) of associates | |||
| and joint ventures | 12 | ( | |
( | |||
Other comprehensive income/(expense) for the year, net of tax | ( | ||
Total comprehensive income/(expense) for the year | ( | ||
| Attributable to: | |||
Shareholders of the Company | ( | ||
Non-controlling interests | |||
( |
2025 | 2024 | ||
| Note | US$m | US$m | |
| Net operating assets | |||
| Fixed assets | 10 | ||
| Right-of-use assets | 10 | ||
| Investment properties | 11 | ||
| Associates and joint ventures | 12 | ||
| Non-current debtors | 13 | ||
| Deferred tax assets | 14 | ||
Pension assets | |||
Non-current assets | |||
| Properties for sale | 15 | ||
| Current debtors | 13 | ||
Current tax assets | |||
| Bank balances | 16 | ||
| Assets classified as held for sale | 17 | ||
Current assets | |||
| Current creditors | 18 | ( | ( |
| Current borrowings | 19 | ( | ( |
Current tax liabilities | ( | ( | |
| Liabilities classified as held for sale | 17 | ( | |
Current liabilities | ( | ( | |
Net current assets | |||
| Long-term borrowings | 19 | ( | ( |
| Deferred tax liabilities | 14 | ( | ( |
| Non-current creditors | 18 | ( | ( |
| Total equity | |||
| Share capital | 20 | ||
Revenue and other reserves | |||
Shareholders’ funds | |||
Non-controlling interests | |||
| Approved by the Board of Directors |
| Attributable to | Attributable | ||||||||
| shareholders | to non- | ||||||||
| Share | Capital | Revenue | Hedging | Exchange | of the | controlling | Total | ||
| capital | reserves | reserves | reserves | reserves | Company | interests | equity | ||
| Note | US$m | US$m | US$m | US$m | US$m | US$m | US$m | US$m | |
| 2025 | |||||||||
At 1 January | ( | ( | |||||||
Total comprehensive income | ( | ||||||||
Dividends paid by the Company | 22 | ( | ( | ( | |||||
| Share-based incentives | 21 | ||||||||
Shares purchased for share-based incentives | ( | ( | ( | ||||||
Repurchase of shares | ( | ( | ( | ( | |||||
Sales of untraceable shares | |||||||||
At 31 December | ( | ( | |||||||
| 2024 | |||||||||
At 1 January | ( | ( | |||||||
Total comprehensive expense | ( | ( | ( | ( | ( | ||||
Dividends paid by the Company | 22 | ( | ( | ( | |||||
| Share-based incentives | 21 | ||||||||
Unclaimed dividends forfeited | |||||||||
At 31 December | ( | ( |
2025 | 2024 | ||
| Note | US$m | US$m | |
| Operating activities | |||
Operating profit/(loss) | ( | ||
| Change in fair value of investment properties | 11 | ( | |
| Depreciation | 4 | ||
| Change in fair value of derivatives | 4 | ||
| Exchange reserve loss realised on distribution | 4 | ||
| Loss on disposal of investment properties | 4 | ||
| Loss on measurement of the disposal group | 4 | ||
| Net gain on disposal of subsidiaries and joint ventures | 4 | ( | ( |
| Net gain on reclassification from properties for sale to investment properties | 4 | ( | |
Decrease in properties for sale | |||
(Increase)/decrease in debtors | ( | ||
Decrease in creditors | ( | ( | |
Interest received | |||
Interest and other financing charges paid | ( | ( | |
Tax paid | ( | ( | |
Dividends from associates and joint ventures | |||
Cash flows from operating activities | |||
| Investing activities | |||
Major renovations expenditure | ( | ( | |
| Repayments from associates and joint ventures | 23 (a) | ||
| Investments in associates and joint ventures | 23 (a) | ( | ( |
| Advances to associates and joint ventures | 23 (a) | ( | ( |
| Disposal of subsidiaries | 23 (c) | ||
| Disposal of joint ventures | 23 (d) | ||
Acquisition of a subsidiary | |||
Proceeds and deposits of disposal of investment properties | |||
Cash flows from investing activities | |||
| Financing activities | |||
| Drawdown of borrowings | 19 | ||
| Repayment of borrowings | 19 | ( | ( |
| Repayments to associates and joint ventures | 23 (a) | ( | ( |
| Advances from associates and joint ventures | 23 (a) | ||
Principal elements of lease payments | ( | ( | |
Dividends paid by the Company | ( | ( | |
Purchase of shares of share-based incentives | ( | ||
Repurchase of shares | ( | ||
Sale of untraceable shares | |||
Cash flows from financing activities | ( | ( | |
Net cash inflow/(outflow) | ( | ||
Cash and cash equivalents at 1 January | |||
Effect of exchange rate changes | ( | ||
| Cash and cash equivalents at 31 December | 23 (b) |